Log In

New? Register Here

Top Biotech & Biopharmaceutical Companies

Google has just Announced a New Health Oriented Company - Calico is a Health Company Focused on Human Health from Extending Life to Increasing Well Being. Read Full Article
Sort By:

Clovis Oncology Inc

Suite 100, 2525 28th Street
BOULDER, CO 80301
http://www.clovisoncology.com
  • Main Phone: (303) 625-5000
  • Fax Number: (303) 245-0360
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Clovis Oncology, Inc. is a United States-based biopharmaceutical company. The Company develops anti-cancer agents. It focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its product candidates includes CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine,; CO-1686, an orally available small molecule epidermal growth factor receptor and CO-338, an orally available, small molecule poly (ADP-ribose) polymerase, or PARP.

Seattle Genetics Inc.

21823 - 30th Drive S.E.
BOTHELL, WA 98021
http://www.seattlegenetics.com
  • Main Phone: (425) 527-4000
  • Fax Number: (425) 527-4001
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.

Onyx Pharmaceuticals Inc.

249 E. Grand Avenue
SOUTH SAN FRANCISCO, CA 94080
http://www.onyx.com/
  • Main Phone: (650) 266-0000
  • Fax Number: (650) 266-0100
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).

Celgene Corporation

86 Morris Avenue
SUMMIT, NJ 07901
http://www.celgene.com/
  • Main Phone: (908) 673-9000
  • Fax Number: (908) 673-9001
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

Baxter International Inc.

One Baxter Parkway
DEERFIELD, IL 60015-4625
http://www.baxter.com/
  • Main Phone: (847) 948-2000
  • Fax Number: (302) 655-5049
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Baxter International Inc. (Baxter) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operated in two segments: BioScience and Medication Delivery. It is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and by patients at home under physician supervision. In February 2012, it acquired Synovis Life Technologies, Inc. In November 2011, it acquired Baxa Corporation. In April 2012, it purchased SIGMA International General Medical Apparatus, LLC.

Amgen Inc.

One Amgen Center Drive
THOUSAND OAKS, CA 91320-1799
http://www.amgen.com
  • Main Phone: (805) 447-1000
  • Fax Number: (805) 447-1010
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In June 12, 2012, the Company acquired substantially all of the outstanding stock of Mustafa Nevzat Pharmaceuticals (MN). In March 7, 2012, the Company acquired Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer.

Vertex Pharmaceuticals Incorporated

130 Waverly Street
CAMBRIDGE, MA 02139
http://www.vrtx.com/
  • Main Phone: (617) 341-6100
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.

Regeneron Pharmaceuticals Inc

STE 10, 777 Old Saw Mill River Road
TARRYTOWN, NY 10591-6707
http://www.regeneron.com/
  • Main Phone: (914) 847-7000
  • Fax Number: (914) 347-2113
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.

AVEO Pharmaceuticals Inc.

75 Sidney Street
CAMBRIDGE, MA 02139
http://www.aveooncology.com/
  • Main Phone: (617) 299-5000
  • Fax Number: (617) 995-4995
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


AVEO Pharmaceuticals, Inc. is a cancer therapeutics company discovering, developing and commercializing targeted cancer therapies. The Company s Human Response Platform, a method of building preclinical models of human cancer, provides the Company with insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. Tivozanib is the Company s lead product candidate, which the Company partnered with Astellas Pharma Inc. (Astellas) during the year ended December 31, 2011. Tivozanib is an inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. In January 2012, the Company announced data from its global, phase III clinical trial of tivozanib, a therapy for first-line treatment in renal cell carcinoma (RCC), which the Company refers to as the TIVO-1 study.

ISIS Pharmaceuticals Inc.

2855 Gazelle Court
CARLSBAD, CA 92010
http://www.isispharm.com/
  • Main Phone: (760) 931-9200
  • Fax Number: (302) 655-5049
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. The Company's principal activity is to develop and market RNA(RiboNucleicAcid)-based novel drugs to treat important diseases such as cardiovascular diseases, diabetes and asthma